DRL_RI, a proposed rituximab biosimilar, shows pharmacokinetic similarity with the US- and EU-approved reference innovator products.

The pharmacodynamics, efficacy, safety, and immunogenicity profiles were also comparable between the proposed biosimilar and reference innovator products.

No clinically meaningful differences in adverse events, B-cell recovery, and immunogenicity were identified between the proposed biosimilar and the reference innovator products during the longer-term follow-up period (up to 52 weeks).